InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.06
(
0.09%
)
Bitcoin
68,446.55
(
-0.09%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: iandy post# 20716

Tuesday, 07/24/2012 10:32:59 AM

Tuesday, July 24, 2012 10:32:59 AM

Post# of 80490
Good point with regard to wild-type EGFR but AP26113 seems tailor-made for the subset of treatment naive NSCLC patients with ALK rearrangements that also have concurrent EGFR activating mutations. http://www.ncbi.nlm.nih.gov/pubmed/21791641

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up